Novo Nordisk A/S (NVO)
| Market Cap | 550.22B |
| Revenue (ttm) | 33.34B |
| Net Income (ttm) | 12.01B |
| Shares Out | 4.34B |
| EPS (ttm) | 2.67 |
| PE Ratio | 47.43 |
| Forward PE | 37.59 |
| Dividend | $0.98 (0.77%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 3,202,847 |
| Open | 126.15 |
| Previous Close | 125.79 |
| Day's Range | 125.99 - 127.90 |
| 52-Week Range | 75.56 - 138.28 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 133.00 (+4.85%) |
| Earnings Date | May 2, 2024 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $133.0, which is an increase of 4.85% from the latest price.
News
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
Novo Nordisk A/S - Articles of Association, April 2024
Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancella...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500
It is understandable for U.S. investors to be focused on the largest technology companies that have driven such strong performance for the S&P 500 over the past decade. But learning about strategies t...
German watchdog approves Novo's acquisition of Cardior Pharmaceuticals
The German cartel office has approved a deal by Denmark's Novo Nordisk to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
NVO, ELF, TAN: Stocks & ETFs to Watch
Mish Schneider discusses her stock and ETF picks as stocks continue to tick lower today. She highlights Novo Nordisk (NVO), E.L.F. Beauty (ELF), and Invesco Solar ETF (TAN). Tune in to find out more a...
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes...
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s...
Popular weight-loss drug doesn't increase suicide risk, EU regulator says
A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a sp...
Wegovy's heart benefits are not just linked with weight loss, new study suggests
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord...
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne...
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Biotech's Next Gold Rush: Weight-Loss Drugs
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
The Seven Wonders of Europe adds to bull market in acronyms
Forget AI plays, meme stocks, gold, even cocoa futures — the biggest bull market right now is in equity acronyms.
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
How Novo Nordisk built an empire selling diabetes and weight-loss drugs
The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy o...